© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Multiple Sclerosis
Digital Therapeutic Shows Promise For MS Fatigue
August 04, 2022
German company says German healthcare system is covering its digital therapeutic called Elevida, which is based on cognitive behavioral therapy.
Intermittent Fasting, Weight Loss Surgery Have Different Outcomes in MS
August 03, 2022
Recent research suggests that bariatric surgery could have an unintended consequence of worsening MS.
Stem Cells Treatments Show Promise in MS
July 07, 2022
Violaine Harris, Ph.D., a senior research scientist with Tisch MS Research Center of New York, discusses new research that shows stem cell treatments can improve disability in patients with MS.
FDA Places Partial Hold on Clinical Trials of MS, Myasthenia Gravis Drug
July 06, 2022
Several cases of liver injury have been identified in phase 3 clinical trials of tolebrutinib.
Black Patients With MS at Higher Risk for Uncontrolled Hypertension
July 01, 2022
Hypertension adversely impacts the multiple sclerosis (MS) disease course and is more common among Black Americans
Vibration Training Enhances Cognition, Quality of Life in MS Patients
June 08, 2022
This is the first study to examine the effects of vibration training on changing cognition and quality of life in people with multiple sclerosis.
MS Leaders Detail Progressive MS Research Advances, Challenges
June 08, 2022
The lack of biomarkers for progressive multiple sclerosis has made the development of new treatments much more difficult for this form of the disease.
Studies Find MS Patients Need Early Help for Pain and Anxiety
June 07, 2022
Screening for depression also should happen quickly to maintain quality of life, two new studies of multiple sclerosis indicate.
Neuropsychiatrist Stresses Importance of Depression-MS Link
May 06, 2022
Anthony Feinstein, Ph.D., of the University of Toronto, author of a new book about multiple sclerosis and mood, says clinicians and patients need to pay more attention to the effects that depression has on the cognitive abilities of patients with the disease.
Real-Word Study Shows Gilenya To Be Effective for MS
May 06, 2022
Study in Czech Republic followed 392 patients for approximately four years.